ArticleMolecular therapy oncolytics2020
The m
Article in Molecular therapy oncolytics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 102 citations in OpenAlex.
- The RNA methylation modification as an immunometabolic regulatory hub in pancreatic cancer: from mechanistic insights to clinical translation perspectives.Molecular cancer · 2026Review
- METTL16 in cancer: Roles and regulatory mechanisms.Genes & diseases · 2026Review
- ALKBH5-mediated m6A regulates the alternative splicing events of SRSF10 in ovarian cancer.Cancer gene therapy · 2025Article
- YTHDC1 mThe EMBO journal · 2024Article
- Clinicopathological Significances and Prognostic Value ofJournal of Cancer · 2023Article
- Targeting FTO Suppresses Pancreatic Carcinogenesis via Regulating Stem Cell Maintenance and EMT Pathway.Cancers · 2022Article
- Article
- Zona Pellucida like Domain Protein 1 (ZPLD1) Polymerization Is Regulated by Two Distinguished Hydrophobic Motifs.International journal of molecular sciences · 2022Article
- The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma.Journal of thoracic disease · 2022Article
- Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer.BMC cancer · 2022Article
- NCancers · 2022Review
- Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma.Scientific reports · 2022Article
- Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer.Scientific reports · 2022Article
- Potential prognosis index for mBMC cancer · 2022Article
- Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents.Journal of personalized medicine · 2022Article
- Analysis and identification of mMolecular therapy. Nucleic acids · 2022Article
- Construction and validation of a novel prognostic model for lung squamous cell cancer based on N6-methyladenosine-related genes.World journal of surgical oncology · 2022Article
- A Signature of NFrontiers in immunology · 2022Article
- Development of a Gene Risk Signature for Patients of Pancreatic Cancer.Journal of healthcare engineering · 2022Article
- Effects of RNA methylation N6-methyladenosine regulators on malignant progression and prognosis of melanoma.Cancer cell international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.